Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

por Matasar, Matthew J., Dreyling, Martin, Leppä, Sirpa, Santoro, Armando, Pedersen, Michael, Buvaylo, Viktoriya, Fletcher, Monique, Childs, Barrett H., Zinzani, Pier Luigi
Publicado 2021

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab

por Morcos, Peter N., Moss, Jonathan, Austin, Rupert, Hiemeyer, Florian, Zinzani, Pier Luigi, Beckert, Vita, Mongay Soler, Lidia, Childs, Barrett H., Garmann, Dirk
Publicado 2023

GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers

por Hartmann, Sylvia, Agostinelli, Claudio, Diener, Jürgen, Döring, Claudia, Fanti, Stefano, Zinzani, Pier Luigi, Gallamini, Andrea, Bergmann, Lothar, Pileri, Stefano, Hansmann, Martin-Leo
Publicado 2012

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

por Pellegrini, Cinzia, Dodero, Anna, Chiappella, Annalisa, Monaco, Federico, Degl’Innocenti, Debora, Salvi, Flavia, Vitolo, Umberto, Argnani, Lisa, Corradini, Paolo, Zinzani, Pier Luigi
Publicado 2016

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

por Cheson, Bruce D., Brugger, Wolfram, Damaj, Gandhi, Dreyling, Martin, Kahl, Brad, Kimby, Eva, Ogura, Michinori, Weidmann, Eckhart, Wendtner, Clemens-Martin, Zinzani, Pier Luigi
Publicado 2016

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

por De Filippi, Rosaria, Morabito, Fortunato, Santoro, Armando, Tripepi, Giovanni, D’Alò, Francesco, Rigacci, Luigi, Ricci, Francesca, Morelli, Emanuela, Zinzani, Pier Luigi, Pinto, Antonio
Publicado 2021

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

por Broccoli, Alessandro, Argnani, Lisa, Cross, Matthew, Janus, Agnieszka, Maitre, Elsa, Troussard, Xavier, Robak, Tadeusz, Dearden, Claire, Else, Monica, Catovsky, Daniel, Zinzani, Pier Luigi
Publicado 2022

Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel

por Pagano, Livio, Zinzani, Pier Luigi, Pileri, Stefano, Quaglino, Pietro, Cuglievan, Branko, Berti, Emilio, Pemmaraju, Naveen, Onida, Francesco, Willemze, Rein, Orfao, Alberto, Barosi, Giovanni
Publicado 2023

Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert Panel

por Zinzani, Pier Luigi, Paulli, Marco, Arcaini, Luca, Della Torre, Emanuel, Ferrero, Simone, Figuera, Amalia, Frigeri, Ferdinando, Martelli, Maurizio, Sabattini, Elena, Scarpa, Riccardo, Barosi, Giovanni
Publicado 2023

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPH...

por Silvestre, Antonio Salar, Trotman, Judith, Sarkozy, Clementine, Song, Yuqin, Sehn, Laurie H., Nastoupil, Loretta J., Zhang, Wanhua, Fustier, Pierre, Delarue, Richard, Zinzani, Pier Luigi
Publicado 2023

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

por Broccoli, Alessandro, Argnani, Lisa, Nanni, Laura, Stefoni, Vittorio, Pellegrini, Cinzia, Casadei, Beatrice, Gugliotta, Gabriele, Carella, Matteo, Coppola, Paolo Elia, Bagnato, Gianmarco, Zinzani, Pier Luigi
Publicado 2023

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013

por Ribrag, Vincent, Armand, Phillippe, Kuruvilla, John, Michot, Jean-Marie, Moskowitz, Craig H, Marinello, Patricia, Snyder, Ellen, Balakumaran, Arun, Shipp, Margaret A, Zinzani, Pier Luigi
Publicado 2015

Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial

por Horwitz, Steven, Zinzani, Pier Luigi, Bagot, Martine, Kim, Youn H., Moskowitz, Alison J., Porcu, Pierluigi, Dwyer, Karen, Sun, Wei, Herr, Fiona M., Scarisbrick, Julia
Publicado 2021

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

por Stefoni, Vittorio, Argnani, Lisa, Carella, Matteo, Casadei, Beatrice, Morigi, Alice, Lolli, Ginevra, Broccoli, Alessandro, Pellegrini, Cinzia, Nanni, Laura, Coppola, Paolo Elia, Zinzani, Pier Luigi
Publicado 2022

Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature

por Bartoli, Lorenzo, Angeli, Francesco, Stefanizzi, Andrea, Fabrizio, Michele, Paolisso, Pasquale, Bergamaschi, Luca, Broccoli, Alessandro, Zinzani, Pier Luigi, Galiè, Nazzareno, Rucci, Paola, Foà, Alberto, Pizzi, Carmine
Publicado 2022

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malign...

por Liu, Chun, Cojutti, Pier Giorgio, Giannella, Maddalena, Roberto, Marcello, Casadei, Beatrice, Cristiano, Gianluca, Papayannidis, Cristina, Vianelli, Nicola, Zinzani, Pier Luigi, Viale, Pierluigi, Bonifazi, Francesca, Pea, Federico
Publicado 2023

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUB...

por Shortt, Jake, Poligone, Brian, Ribrag, Vincent, Zinzani, Pier Luigi, El-Sharkawi, Dima, Walewski, Jan, Prica, Anca, Wilson, Laksmi, Souza, Sonia, Keer, Harold, Taylor, Jason, Marchi, Enrica
Publicado 2023

Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis

por Ferreri, Andrés J. M., Zinzani, Pier Luigi, Messina, Carlo, Valsecchi, Diletta, Rendace, Maria Chiara, Premoli, Eleonora, Giacomini, Elisa, Veronesi, Chiara, Degli Esposti, Luca, Di Matteo, Paola
Publicado 2023

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial

por Pettengell, Ruth, Sebban, Catherine, Zinzani, Pier Luigi, Derigs, Hans Gunter, Kravchenko, Sergey, Singer, Jack W., Theocharous, Panteli, Wang, Lixia, Pavlyuk, Mariya, Makhloufi, Kahina M., Coiffier, Bertrand
Publicado 2016

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma

por Casadei, Beatrice, Argnani, Lisa, Morigi, Alice, Lolli, Ginevra, Broccoli, Alessandro, Pellegrini, Cinzia, Nanni, Laura, Stefoni, Vittorio, Coppola, Paolo E., Carella, Matteo, Cavo, Michele, Zinzani, Pier Luigi
Publicado 2020